Sigma's Biologic Oncaspar (Pegaspargase) Receives Approval in the U.S.
Sigma Tau`s Oncospar (Pegaspargase) Receives Supplemental Approval in US
Sigma-tau Arzneimittel GmbH Chenodeoxycholic acid sigma-tau (chenodeoxycholic acid) Receives Approval In Europe
Rare disease specialist Sigma-Tau Pharmaceuticals has appointed Michael Minarich as chief executive officer.